{"nctId":"NCT00218426","briefTitle":"Addiction Treatment in Russia: Oral vs. Naltrexone Implant","startDateStruct":{"date":"2006-07","type":"ACTUAL"},"conditions":["Heroin Dependence","Opioid-Related Disorders"],"count":306,"armGroups":[{"label":"ONP + DNI","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: naltrexone implant","Drug: oral placebo naltrexone"]},{"label":"ON + DNIP","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oral naltrexone","Drug: placebo implant"]},{"label":"ONP + DNIP","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: oral placebo naltrexone","Drug: placebo implant"]}],"interventions":[{"name":"naltrexone implant","otherNames":["DNI"]},{"name":"oral naltrexone","otherNames":["ON"]},{"name":"oral placebo naltrexone","otherNames":["ONP"]},{"name":"placebo implant","otherNames":["DNIP"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Current opioid dependence\n* Recently completed opioid detoxification\n\nExclusion Criteria:\n\n* Serious medical or psychiatric condition requiring immediate hospitalization or that would make participation in the study hazardous\n* Planning to leave the study area within the 12 months following study entry\n* Imminent incarceration\n* Pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Retention Without Relapse to Heroin Addiction (Measured at Month 6)","description":"Survival analysis (Kaplan-Meier survival functions with log-rank Cox-Mantel criteria for group comparison was used to determine the primary outcome of retention, defined as not missing 2 consecutive counseling sessions and not having a relapse. Because this outcome combined patients who failed to keep appointments with those who kept appointments but relapsed, the proportion of non-survivors attributable to proven relapse.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Dropped Out of Treatment","description":"Kaplan-Meier survival curves for the event of subjects who dropped out of treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Positive Opioid Urine Test","description":"missed urine tests were imputed to be positive for opiates","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".427","spread":null},{"groupId":"OG001","value":".636","spread":null},{"groupId":"OG002","value":".341","spread":null}]}]}]},{"type":"SECONDARY","title":"Use of Alcohol","description":"use of alcohol grams per day","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"1.7"},{"groupId":"OG001","value":"9.0","spread":"1.7"},{"groupId":"OG002","value":"9.6","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Composite Score of Psychiatric Problems","description":"composite score is a decimal score; with 0 = no problems, 1 = the most problems based on the Addiction Severity Index composite score of 11 indexed questions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.02"},{"groupId":"OG001","value":"0.15","spread":"0.02"},{"groupId":"OG002","value":"0.18","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"HIV Risk (Baseline)","description":"The Risk Assessment Behavior (RAB), is an HIV risk Scale. The Total Score is scored by adding the values that correspond to the responses selected by the subject for the items asked. This highest total score is 40 (highest risk), and the lowest score = 0 (no risk). This assessment has 2 Subsections: 1) Drug Risk = 8 questions (lowest Drug Risk score = 0 (no risk), and highest drug risk score = 22 =(greatest risk), 2) 10 Sex Risk questions: scores are 0 = no risk, and 18 = highest risk). Total RAB Score = Drug Risk Total + Sex Risk Total (0 = no risk, 40 = highest). See: Risk Assessment Battery (RAB) Scoring System, https://www.med.upenn.edu/hiv/assets/user-content/.../RABScoringv2.112.21.95.doc","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"0.44"},{"groupId":"OG001","value":"8.0","spread":"0.47"},{"groupId":"OG002","value":"8.7","spread":"0.49"}]}]}]},{"type":"SECONDARY","title":"Global Assessment Form (GAF)","description":"Assessment of overall psychiatric function comprises Axis V in the DSM-IV (DSM-IV, 1994). GAF scores range from 0 to 100. A reasonably well-functioning person will score above 70; serious impairment is below 50.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.8","spread":"0.7"},{"groupId":"OG001","value":"64.7","spread":"0.8"},{"groupId":"OG002","value":"62.5","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Amphetamine Drug Use","description":"Number of subjects who used Amphetamine in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel \\& Sobel, 1992).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Cocaine Drug Use","description":"Number of subjects with cocaine drug use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel \\& Sobel, 1992).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Marijuana Drug Use","description":"Number of subjects with Marijuana use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel \\& Sobel, 1992).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Benzodiazepine Drug Use","description":"Number of subjects with benzodiazepine drug use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel \\& Sobel, 1992).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":102},"commonTop":["local site reaction","nausea","drowsiness","increased liver enzyme","bronchitis"]}}}